Retraction notice to “Differential effects of valproic acid on growth, proliferation and metastasis in HTB-5 and HTB-9 bladder cancer cell lines” [Canc. Lett. 281/2 (2009) 196–202] (Cancer Letters (2009) 281(2) (196–202), (S0304383509001426), (10.1016/j.canlet.2009.02.045));Differential effects of valproic acid on growth, proliferation and metastasis in HTB5 and HTB9 bladder cancer cell lines

Cancer Letters

Volumn 281, Issue 2, 2009, Pages 196-202

  Byun, Seok Soo ^a   Kim, Fernando J ^a,b   Khandrika, Lakshmipathi ^a   Kumar, Binod ^a   Koul, Sweaty ^a   Wilson, Shandra ^a,b   Koul, Hari K ^a,b  

^a Division of Urology   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Bladder cancer; HTB5; HTB9; Muscle invasive; Valproic acid

Indexed keywords

VALPROIC ACID;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; METASTASIS; METASTASIS INHIBITION; PRIORITY JOURNAL;

EID: 67349285166     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2021.08.010     Document Type: Erratum

References (34)

1. Cancer Facts and Figures 2008, American Cancer Society. .
2. Rubben H., Lutzeyer W., Ficsher N., Deutz F., Lagrange W., and Giani G. Natural history and treatment of low and high risk superficial bladder tumors. J. Urol. 139 (1988) 283-285
3. Steinberg G.D., Trump D.L., and Cummings K.B. Metastatic bladder cancer: natural history, clinical course and consideration for treatment. Urol. Clin. North Am. 9 (1992) 735-746
4. Manoharan M., and Soloway M.S. Superficial transitional cell carcinoma of the bladder: management and prognosis. In: Richie J.P., and D' Aamico A.V. (Eds). Urologic Oncology (2005), Elsevier Saunders, Philadelphia 317-337
5. Hendricksen K., and Witjes J.A. Intravesical gemcitabine: an update of clinical results. Curr. Opin. Urol. 16 (2006) 361-366
6. McKiernan J.M., Masson P., Murphy A.M., Goetzl M., Olsson C.A., Petrylak D.P., Desai M., and Benson M.C. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J. Clin. Oncol. 24 (2006) 3075-3080
7. Galsky M.D., Mironov S., Iasonos A., Scattergood J., Boyle M.G., and Bajorin D.F. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest. New Drugs 25 (2007) 265-270
8. Siefker-Radtke A. Systemic chemotherapy options for metastatic bladder cancer. Expert Rev. Anticancer Ther. 6 (2006) 877-885
9. Johanssen C.U. Mechanisms of action of valproate: a commentary. Neurochem. Int. 37 (2000) 103-110
10. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., and Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276 (2001) 36734-36741
11. Gottlicher M., Minucci S., Zhu P., Krämer O.H., Schimpf A., Giavara S., Sleeman J.P., Lo Coco F., Nervi C., Pelicci P.G., and Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20 (2001) 6969-6978
12. Chinnaiyan P., Cerna D., Burgan W.E., Beam K., Williams E.S., Camphausen K., and Tofilon P.J. Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin. Cancer Res. 14 (2008) 5410-5415
13. Joseph J., Mudduluru G., Antony S., Vashistha S., Ajitkumar P., and Somasundaram K. Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB. Oncogene 23 (2004) 6304-6315
14. Kim S.H., Ahn S., Han J.W., Lee H.W., Lee H.Y., Lee Y.W., Kim M.R., Kim K.W., Kim W.B., and Hong S. Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Biochem. Biophys. Res. Commun. 315 (2004) 964-970
15. Dyer E.S., Paulsen M.T., Markwart S.M., Goh M., Livant D.L., and Ljungman M. Phenylbutyrate inhibits the invasive properties of prostate and breast cancer cell lines in the sea urchin embryo basement membrane invasion assay. Int. J. Cancer 101 (2002) 496-499
16. Tang X.X., Robinson M.E., Riceberg J.S., Kim D.Y., Kung B., Titus T.B., Hayashi S., Flake A.W., Carpentieri D., and Ikegaki N. Favorable neuroblastoma genes and molecular therapeutics of neuroblastoma. Clin. Cancer Res. 10 (2004) 5837-5844
17. Coradini D., Zorzet S., Rossin R., Scarlata I., Pellizzaro C., Turrin C., Bello M., Cantoni S., Speranza A., Sava G., Mazzi U., and Perbellini A. Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin. Cancer Res. 10 (2004) 4822-4830
18. Chen C.L., Sung J., Cohen M., Chowdhury W.H., Sachs M.D., Li Y., Lakshmanan Y., Yung B.Y., Lupold S.E., and Rodriguez R. Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. J. Pharmacol. Exp. Ther. 319 (2006) 533-542
19. Angelucci A., Valentini A., Millimaggi D., Gravina G.L., Miano R., Dolo V., Vicentini C., Bologna M., Federici G., and Bernardini S. Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways. Anticancer Drugs 17 (2006) 1141-1150
20. Sharma S., Symanowski J., Wong B., Dino P., Manno P., and Vogelzang N. A phase II clinical trial of oral valproic acid in patients with castration-resistant prostate cancers using an intensive biomarker sampling strategy. Transl. Oncol. 1 (2008) 141-147
21. Kumar B., Koul S., Khandrika L., Meacham R.B., and Koul H.K. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res. 68 (2008) 1777-1785
22. Chaturvedi L.S., Koul S., Sekhon A., Bhandari A., Menon M., and Koul H.K. Oxalate selectively activates p38 mitogen-activated protein kinase and c-Jun N-terminal kinase signal transduction pathways in renal epithelial cells. J. Biol. Chem. 277 (2002) 13321-13330
23. Franken N.A., Rodermond H.M., Stap J., Haveman J., and van Bree C. Clonogenic assay of cells in vitro. Nat. Protoc. 1 (2006) 2315-2319
24. Repesh L.A. A new in vitro assay for quantitating tumor cell invasion. Invas. Metast. 9 (1989) 192-208
25. Dinney C.P. Therapy of invasive bladder cancer. Urology 67 (2006) 56-59
26. Bruins H.M., and Stein J.P. Risk factors and clinical outcomes of patients with node-positive muscle-invasive bladder cancer. Expert Rev. Anticancer. Ther. 8 (2008) 1091-1101
27. Liu T., Kuljaca S., Tee A., and Marshall G.M. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat. Rev. 32 (2006) 157-165
28. Catalano M.G., Fortunati N., Pugliese M., Costantino L., Poli R., Bosco O., and Boccuzzi G. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J. Clin. Endocrinol. Metab. 90 (2005) 1383-1389
29. Marks P.A., Richon V.M., Kelly W.K., Chiao J.H., and Miller T. Histone deacetylase inhibitors: development as cancer therapy. Novartis Found. Symp. 259 (2004) 269-281
30. Marks P.A., Richon V.M., Miller T., and Kelly W.K. Histone deacetyl-ase inhibitors. Adv. Cancer Res. 91 (2004) 137-168
31. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1 (2002) 287-299
32. Xia Q., Sung J., Chowdhury W., Chen C.L., Höti N., Shabbeer S., Carducci M., and Rodriguez R. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res. 66 (2006) 7237-7244
33. Stadler W.M., Margolin K., Ferber S., McCulloch W., and Thompson J.A. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin. Genitourin. Cancer 5 (2006) 57-60
34. Li X.N., Shu Q., Su J.M., Perlaky L., Blaney S.M., and Lau C.C. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol. Cancer Ther. 4 (2005) 1912-1922